Clinical Trials

Triple Negative Breast Neoplasms

NCT05673200 2026-03-18

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Phase 1 Recruiting

32 enrolled

Triple Negative Breast Neoplasms

NCT07137416 2026-03-18

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Phase 1 Recruiting

36 enrolled

Phase 3 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT02954874 2026-03-17

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

1,155 enrolled

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05111561 2026-03-17

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

Phase 1 Suspended

42 enrolled

Phase 1/2 Active not recruiting

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT01116648 2026-03-05

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

155 enrolled 34 charts

Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms

NCT07067138 2026-03-03

A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)

Phase NA Recruiting

175 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05035407 2025-12-02

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

36 enrolled 7 charts

Phase 1 Active not recruiting

Carcinoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT01251874 2025-11-21

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer

44 enrolled

Phase 1 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03218826 2025-10-30

PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery

23 enrolled 15 charts

BreastGenitourinary

Breast Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT02883062 2025-10-16

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

Phase 2 Active not recruiting

67 enrolled 16 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00861705 2025-09-30

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

454 enrolled 23 charts

Phase 2 Active not recruiting

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT02498613 2025-09-25

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

122 enrolled 16 charts

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06590558 2025-07-03

Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer

Phase 1 Withdrawn

Triple Negative Breast Neoplasms

NCT02595905 2025-05-16

Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

344 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01349959 2025-04-27

Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer

58 enrolled 16 charts

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT00576654 2025-04-15

Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery

73 enrolled

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT02898207 2023-04-26

Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

28 enrolled 21 charts

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT02474173 2022-11-04

Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer

31 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03394027 2022-08-23

ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

30 enrolled 15 charts

Neoplasm Metastasis, Endometrial Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT04296942 2022-01-11

BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)

1 enrolled 10 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01445418 2019-10-22

AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer

103 enrolled

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT01964924 2019-09-20

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer

37 enrolled 17 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03326258 2018-07-18

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

Phase 1/2 Withdrawn

BreastDermatologic

Uveal Melanoma, Breast Neoplasms, Melanoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT00892736 2018-06-29

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

BreastGastrointestinalGenitourinaryGynecologic

98 enrolled

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Hereditary Breast and Ovarian Cancer Syndrome, Triple Negative Breast Neoplasms

NCT01624441 2018-03-30

Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer

40 enrolled

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT01145430 2017-12-22

Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer

45 enrolled

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT01319539 2017-08-30

MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

Phase 2 Terminated

12 enrolled 9 charts

BreastGastrointestinalGynecologicHead & NeckOther solid neoplasmThoracic

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02567396 2017-04-24

Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Phase 1 Withdrawn

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT01151449 2017-04-11

Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer

Phase 2 Terminated

6 enrolled 8 charts

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT01575522 2016-03-21

Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer

22 enrolled 10 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01276496 2016-03-15

Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery

13 enrolled

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT01238133 2015-09-04

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer

14 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01071564 2015-04-15

RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery

13 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00031681 2013-09-30

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)